SCLERODERMA was once thought to be a disease limited to the skin, but recent reports have emphasized involvement of the gastrointestinal tract,1 heart,2 lungs,3 kidneys,4 endocrine glands, bones, and skeletal muscle.1 It is now thought that scleroderma is a systemic disease, and Goetz5 has suggested that a more appropriate name would be progressive systemic sclerosis, of which skin involvement is only one manifestation. In the early descriptions of generalized scleroderma, dyspnea and a tendency to pulmonary infections were attributed to restrictions of respiratory movements produced by sclerotic changes in the skin and muscles of the chest wall. Now it seems more likely that the pulmonary symptoms are due to fibrotic changes in the lungs. In 1891 Finlay6 recognized the association between scleroderma and pulmonary fibrosis, while Lewin and Heller,7 in 1895, and later Matsui8 demonstrated pulmonary fibrosis at autopsy in cases of scleroderma. The roentgenological featuresof pulmonary fibrosis
SHUFORD WH, SEAMAN WB, GOLDMAN A. PULMONARY MANIFESTATIONS OF SCLERODERMA. AMA Arch Intern Med. 1953;92(1):85–97. doi:10.1001/archinte.1953.00240190097007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.